Alnylam Pharmaceuticals (ALNY) was Downgraded by Morgan Stanley to ” Equal-Weight”. Earlier the firm had a rating of “Overweight ” on the company shares. Morgan Stanley advised their investors in a research report released on Oct 7, 2016.
Many Wall Street Analysts have commented on Alnylam Pharmaceuticals. Alnylam Pharmaceuticals was Initiated by Morgan Stanley to “Overweight” on Aug 2, 2016.
On the company’s financial health, Alnylam Pharmaceuticals reported $-1.05 EPS for the quarter, beating the analyst consensus estimate by $ 0.22 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $-1.27. The company had revenue of $8.70 million for the quarter, compared to analysts expectations of $7.98 million. The company’s revenue was up .2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.85 EPS.
Alnylam Pharmaceuticals opened for trading at $68.22 and hit $69.69 on the upside on Tuesday, eventually ending the session at $68.57, with a gain of 0.50% or 0.34 points. The heightened volatility saw the trading volume jump to 5,60,922 shares. Company has a market cap of $5,878 M.
In a different news, on Apr 21, 2016, John Maraganore (Chief Executive Officer) sold 30,151 shares at $67.87 per share price. According to the SEC, on Mar 10, 2016, Michael W Bonney (director) purchased 2,000 shares at $58.36 per share price. On Dec 4, 2015, Philip A Sharp (director) sold 30,000 shares at $109.00 per share price, according to the Form-4 filing with the securities and exchange commission.
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics based on its ribonucleic acid interference (RNAi). The Companys pipeline focuses in three strategic therapeutic areas (STArs): Genetic Medicines with a pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease with a pipeline of RNAi therapeutics toward genetically validated liver-expressed disease in cardiovascular and metabolic diseases and hepatic infectious disease with a pipeline of RNAi therapeutics for treatment of hepatic infectious diseases. Its products include Patisiran (ALN-TTR02) Revusiran (ALN-TTRsc) ALN-AT3 ALN-CC5 ALN-AS1 ALN-AAT ALN-GO1 ALN-TMP ALN-PCS ALN-PCSsc ALN-AC3 ALN-ANG ANGPTL3 ALN-HBV ALN-HDV and ALN-PDL. The Company is developing two investigational RNAi therapeutic candidates for TTR-Mediated Amyloidosis (ATTR): patisiran and revusiran.